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Humanepidemiology andexperimental animal datahaveprovidedthestatistical association andbiologicalinforma-
tion necessary to proposethataflatoxins arerisk factors forhumanliver cancer. Aslivercancercauses at least200,000
deaths peryear, prevention measuresmustbedevelopedtoamelioratethisnearlyalwaysfataldisease. Preventivestrategies
will be facilitated by theidentification ofindividuals at high risk. It isthegoalofthemolecular dosimetry field to pro-
videfacileandaccurate biomarkers toidentify peopleathighriskforcarcminogenexposureandconsequentadversehealth
effects. Wehavedeveloped methodstodetectthemajoraflatoxinDNAadduct,aflatoxinN7-guanine(AFB-N7-guanine),
in urine, examined thedose-responsecharacteristics inpeoplelivinginChinaandTheGambia, andhavefoundanex-
cellent association of this biomarker with exposure. In addition to exposure studies in people, our laboratories have
monitored AFB-N7-guanineexcretion intheurineofratswhoseriskfordevelopingcancerhasbeenmodultedwithdietary
chemoprotective agentssuchthatindependentgroupsofanimalsreceivingthesamedosageofaflatoxinB1 wereateither
high orlowriskfortumorigenesis. TheproductionofDNAdamagebyaflatoxinsisnottheexclusivemechanismforliver
cancer. Manyotherfactors,indudinghepatitisBvirus,cellproliferation,andnutritionalstatus,canexertstrongmodifica-
tioneffects inhuman disease. Thus, molecularepidemiologicalinvestigtionsthatexamineonlyonebiomarkermaygreatly
underestimate oroverestimatetheriskforanindividual. Inourexperimentalstudies, wehavefoundtheneedtomeasure
specific, biologically relevant metabolites inaurinesample. Ourdatashowthatthelevelsofthedailyurinaryexcretion
oftotalaflatoxinmetabolitesareunrelated toriskofaflatoxin-induced disease. Similaranalysesusingthehuman urine
samplesfromChinaalsorevealedthattotalaflatoxinmetabolitesinurinedonotreflectappropriateexposureassessments.
Inthe rat model, AFB-N7-guanine is aminor, butbiologically relevant, metaboliterepresenting lessthan 1% ofthe ex-
creted materialinurine, whichdoesreflectexposureinexperimentalmodels. Thus, thecompositehumanandexperimental
datagenerated fromour research indicatesthat acautiousinterpretationoftherelationshipbetweenanybiomarkerand
tumoroutcome mustbeemployed. However, bothexperimental ratdataandhumanstudieshavealsofoundthattheAFB-
N7-guanine adduct inurineisagood, noninvasive, short-term biomarkerfordetermining bothaflatoxin exposureand
risk ofgenetic damage in target organs.
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Introduction
Humanepidemiology andexperimental animaldatahavepro-
vided the statistical association and biological information
necessary to suggest that aflatoxins are risk factors for human
liver cancer (1,2). Thedegreethataflatoxins contribute to this
diseasewillbeinfluencedby anumberofhumanhealthfactors,
including hepatitisBvirus infection, nutritional status, andage
as well as the extent ofaflatoxin exposure (2). As liver cancer
causes at least 200,000 deaths worldwide per year, prevention
measuresmustbedevelopedtoreducetheincidenceofthislarge-
ly fatal disease. Preventive strategies will be facilitated by theGROOPMANETAL.
identification of individuals at high risk. It is the goal of the
moleculardosimetry fieldtoprovidereliablebiomarkerstoiden-
tify people athigh risk forcarcinogenexposureandconsequent
adversehealtheffects. Methodshavebeendevelopedtodetectthe
major aflatoxin-DNA adduct, aflatoxin-N7-guanine (AFB-N7-
guanine), in urine and thus allowed the dose-response char-
acteristics ofthis biomarkertobeexamined inhumans(3-6). In
addition, complementaryapproacheshavebeenvalidatedforthe
measurementofaflatoxinboundtoperipheralbloodalbumin; the
propertiesofthisapproachhavebeendiscussedelsewhere (7,8).
The AFB-N7-guanineadducthas beenmonitored intheurineof
rats whose riskfordeveloping livercancerhasbeenmodulated
with dietary chemoprotective agents such that independent
groupsofanimalsreceivingthesamedoseofaflatoxinB1 (AFB,)
were at either high or low risk for tumorigenesis (9,10). These
complementary humanandexperimental datahavebeenusedto
evaluate AFB-N7-guanine excretion in urine as anoninvasive,
short-term biomarker fordetermining both aflatoxin exposure
and riskofgenetic damage in targetorgans.
AFB-N7-Guanine in Human Urine:
Studies in China
Livercanceristhethirdleading causeofcancer-related deaths
inChina, andthereareregionsofthecountry wherethisdisease
isveryprevalent. TheGuanxgiAutonomousRegionisamongthe
areas withthehighest incidence oflivercancer. Weinitiated the
following study toexaminebiomarkers foraflatoxin exposures.
The dietary intake ofaflatoxins was monitored for 1 week in a
studygroupconsistingof30malesand 12females, agesranging
from 25 to 64 years, living in Fusui county, Guangxi Autono-
mousRegion, China(4,5). ThevastmajorityofAFB, exposure
was fromcontaminatedcorn. Theaverage maleintakeofAFB,
was48.4jAgperday, giving atotal meanexposureoverthestudy
periodof276.8tsg. Theaveragefemaledailyintakewas92.4jig
perday, resulting inatotalaverageexposureoverthe7-dayperiod
of542.6ytgAFBI. Themaximumintakeforthemaleandfemale
subjects over the 1-week collection was 963.9 and 1035 ytg,
respectively, and the minimum exposure for male and female
subjects was56.7and90ZgAFB1, respectively. Total24-hrurine
samples werecollected startingonthefourthdayasconsecutive
12-hr fractions.
Total aflatoxinmetabolitesintheurinesamplesweremeasured
by competitive radioimmunoassay using amonoclonal antibody
that recognizes AFBI, aflatoxin P1 (AFP,) and aflatoxin Ml
(AFM,) with equal affinity and cross-reacts with AFB-N7-
guanine with 5- to 10-fold less affinity. A depiction of the
statistical association between AFB, intake per day and total
aflatoxinmetaboliteexcretionperdayisshowninFigure 1, and
the correlation coefficient of 0.26 only reaches a statistical
significance level of 0.10. Thus, total metabolites in urine as
measuredbythis monoclonalantibodydonotprovidedatatoin-
dicate that total metabolites were an appropriate dosimeter
measurement for exposure status.
Thesedatapromptedananalysisoftheurinesamplesby com-
binedpreparativemonoclonalantibodyaffinitychromatography/
analytical HPLC to determine levels of individual aflatoxin
metabolites. Nearly 550individualanalytical HPLCswereper-
formed. AFB-N7-guanine, AFMI, AFP,, and AFB, were the
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FIGURE 1. Linearregressionanalysisofthetotal aflatoxinsinurineofmales
and females measured by a monoclonal antibody-based radioimmunoassay
compared with dietary aflatoxin intake perday (5).
aflatoxins mostcommonly detected andquantified intheurine
samples. PresentedinFigure2 arethelinearregressionanalyses
fortheurinary levelsofthese individual aflatoxinscompared to
aflatoxin intake. The intake data represent the AFB, exposure
from the day before the specific urine collection. Figure 2A
showsthecorrespondencebetweenAFB-N7-guanineadduct ex-
cretionwithintake, where acorrelationcoefficientof0.65 with
ap value of < 0.000001 results. Figure2Bdepictsthe analysis
for AFM1, in which a correlation coefficient of0.55 with a p
valueof < 0.00001 weredetermined. Figure2CrepresentsAFPI
excretion. There was nopositive statistical association between
exposure in the diet and AFPI excretion in urine. Further, it
shouldbenotedthatAFP1 contributessubstantiallytotheoverall
levels of aflatoxins in the urine samples as detected by com-
petitive radioimmunoassay (see Fig. 1), thereby masking the
associationbetween exposureandminormetabolites. However,
theresolutionofthetotalaflatoxinmetabolitecontentintheurine
permitstheassociationofAFB-N7-guanine andAFM, excretion
asbiomarkers ofexposure to be revealed.
One objective ofthis study was to determine the number of
samples required from anindividualandthetimeframefor sam-
plecollection necessary to validate abiomarker as reflecting a
biologically effective doseofAFB, inhumans. There was par-
ticular interest in characterizing the molecular dosimetry of
AFB-N7-guanine because of the putative relationship of this
metabolitewiththecancerinitiation process. Figure3 showstotal
AFB-N7-guanine excretion in theurineofthe male and female
subjects overthecompleteurinecollectionperiodplottedagainst
thetotalAFB, exposure inthedietforeachofthesubjects. This
analysis smoothstheday-to-day variations inbothintakeand ex-
cretion ofAFB-N7-guanine andreveals acorrelationcoefficient
of 0.80 and a p value of < 0.0000001. This analysis clearly
demonstratesthat asummationofexcretionand exposure status
provides a strongerassociationbetween exposureand amolecu-
lardosimetrymarkerthan was seeninpriorstatistical analyses
(see Fig. 2A) and supports the concept that quantitation ofthe
AFB-N7-guanine adduct in urine is a reliable biomarker for
AFB, exposures.
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FIGURE 2. Linearregressionanalysis ofdaily (A) aflatoxin (AFB) N7-guanine, (B)AFMI, (C) AFP,, and (D) AFBI inurinecompared withdietaryaflatoxin in-
take from the previous day (5).
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FIGURE 3. Linear regression analysis of the association between total
aflatoxin-N7-guanine adductexcretion inurine from malesand females with
total dietary aflatoxin exposure during the study period (5).
AFB-N7-Guanine in Human Urine:
Studies in The Gambia, West Africa
Multiple risk factors for human liver cancer exist, and the
following study was undertaken toexplore the relationship be-
tween two of these factors by examining dietary exposure to
aflatoxins and excretion of AFB-N7-guanine in the urine of
chronicallyexposedpeoplewho wereeitherpositive ornegative
forthesurfaceantigenofhepatitisBvirus(6,11). Thedietsof20
individuals, 10 males and 10 females, ages 15-56 years, were
monitored for 1 weekandlevelsofdaily aflatoxin intakedeter-
mined. Starting on the fourth day, total 24-hr urines were col-
lected consecutively for4days.
Preparative monoclonal antibody affinity chromatography/
HPLC wasdone oneachoftheurine samples and the relation-
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FIGURE 4. Linear regressionanalysis ofthe associationbetween total aflatox-
inN7-guanineadductexcretioninurineanddietaryaflatoxin intakeduring
the study period (11).
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ships between excretion ofAFB-N7-guanine with aflatoxin in-
takedetermined. Figure4depictstherelationshipbetween total
AFB-N7-guanine excretion in the urine ofthe male and female
subjects overthe 4-day collection period with the total aflatox-
in exposure inthediet. Linearregression analysis reveals a cor-
relationcoefficientof0.82 and apvalueof < 0.0000001. Given
thesedata, itisclearthat asummationofexcretionand exposure
status over the collection period, similar to the experience in
Chinadescribed above, provides strong evidence fortheutility
ofAFB-N7-guanine in urine as an appropriate molecular do-
simetry marker ofexposure.
Interestingly, inthis study, apolyclonalantibody used to meas-
ure total urinary metabolites showed a good correlation
(r = 0.65) between this end point and aflatoxin intake (12), in
contrast to the study in China. This can probably be explained
by differing specificity, as discussedpreviously (11). Thepoly
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FIGURE 5. Linear regression analysis ofthe aflatoxin-N7-guanine excretion in
urinecompard with thetotal aflatoxin intake perday, dissociated forhepatitis
B virus surface antigen carrier and noncarrier status (11).
clonal antibody used in The Gambia binds AFPI poorly com-
pared to themonoclonal antibody used in China. These sort of
considerations complicate the quantitative aspects of this
approach.
Thisinvestigationalsoprovided anopportunity toexaminethe
roleofchronic hepatitis B virus infection in the metabolism of
aflatoxins. Figure 5 showsthe statistical analysis oftheassocia-
tion ofhepatitis B virus status and the excretion of the AFB-
N7-guanineadductinurineforallsubjects. Thesedatarevealthat
although considerable interindividual differences exist for the
ability to convert AFBI to its genotoxic metabolite, AFB-N7-
guanine, thisdid not relate to HBV carrier status.
AFB-N7-Guanine in Rat Urine: Single-
Dose Studies
Theanalysis ofthekinetics ofAFB-N7-guanine excretion in
urine arecomplicatedinhumansbecauseoftheday-to-day fluc-
tuations in exposures. Thus, studies in rats using a single ex-
posure toAFBI have beenused to characterize these excretion
kinetics. Urines werecollected over24hrfrom 12maleF344 rats
dosed orally at levels ranging from 0.030 to 1.00 mg AFB1/kg
body weight (13). Aliquots of each urine were preparatively
purified by immunoaffinity chromatography. A HPLC profile
from oneofthe raturinesamples is showninFigure6. Inthe up-
per left panel ofFigure 6 is the UV-visible spectrum obtained
fromthediode-array detectorfortheAFB-N7-guanine adduct.
AFB-N7-guanine, AFQ1, AFP1, AFM,, and AFB1 account for
7.5, 3.0, 31.5,2.2, and0.3% ofthetotalaflatoxins injected onthe
HPLC, respectively. All ofthe othermajor peaks absorbing at
363 nm showcharacteristic UV-visible spectraofaflatoxins, but
their structures have not yetbeen elucidated.
TherelationshipbetweenAFB, doseandtheexcretion ofthe
AFB-N7-guanine adduct over the24 hrfollowing exposure was
then determined (Fig. 7) with a correlation coefficient and r2
value of 0.99 and 98.33%, respectively. This analysis dem-
onstrates an excellent linear correspondence between oral
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FIGURE 6. Analytical HPLC profile ofa rat urine sample obtained from ananimal dosed at I mg aflatoxin B1 (AFB,)/kg body weight and the urine collected for
48 hrafterdosing. Theurine wasprepared using threedifferent monoclonal antibodies bound to an immunoaffinity column. (A) UV-visible spectrum ofAFB-
N7-guanine adduct. (B) HPLC profile from Oto 70min, showing the contribution ofAFM 1 tototal aflatoxins. (C) HPLC profile from 0 to 70min showing the
AFB-N7-guanine, AFQ,, AFM,, and AFP, in greater detail (13).
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FIGURE 7. Linear regression analysis of the excretion of aflatoxin-N7-guanine
in urine over24 hr compared with the dose ofaflatoxin B, (13).
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FIGURE 8. Linear regression analysis comparing the excretion ofaflatoxin-
N7-guanine inurine over a24-hrperiod withthe residual aflatoxin-DNA ad-
ducts in the liver at 24 hr afterdosing (13).
dose and excretion ofabiologically relevant metabolite in urine.
In contrast, other oxidative metabolites such asAFP, revealed
no linearexcretion characteristics (data not shown). Finally, at
24hrafterdosing, the residual level ofaflatoxin liver DNA ad-
ducts weredetermined andcompared toAFB-N7-guanine excre-
tion in urine (Fig. 8). The correlation coefficient and r2 values
were0.98 and96.3%, respectively, supportingtheconceptthat
measurement ofthe AFB-N7-guanine adduct in urine reflects
DNA damage in the primary target organ.
AFB-N7-Guanine in Rat Urine:
Biomarker for Risk in Chronically Ex-
posed Rats
The risk for aflatoxin hepatocarcinogenesis can be modified
in animals by using a number of chemoprotective agents, in-
cludingphenolic antioxidants, ethoxyquin, anddithiolethiones.
A particularly effective cancer chemoprotective agent for
aflatoxin carcinogenesis is a substituteddithiolethione, oltipraz
(14). MaleF344 rats werefed apurifieddietsupplemented with
0.075% w/woltipraz for4 weeks. Inthis study rats received 10
intragastric dosesofAFB, (25 ,tg/rat/day; days 8-12 and 15-19),
andthis 10-dose exposure toAFBI produced an 11% incidence
ofhepatocellular carcinomaat23 months, withanadditional9%
oftheratsexhibitinghyperplastic nodulesintheirlivers. Incon-
trast, feedingratsadietsupplementedwith0.075% oltipraz for
a4-weekperiodnearthetimeofAFB1 exposureaffordedcom-
plete protection against AFBI-induced hepatocellular car-
cinomas andhyperplastic nodules. None ofthese lesions were
observed intheoltipraz-fed, AFB,-treatedanimals. Further, no
tumors were at secondary, extrahepatic sites for AFB, car-
cinogenesis such as the colon and kidney. Thus, the chemo-
protection model affords us an experimental system to answer
basic questionsabouttherelationships between levelsofAFB-
N7-guanine in urine for high- and low-riskanimals.
Structure-activity studieswithdithiolethione indicatedthatthe
cancer chemoprotective activity ofoltipraz is exclusively em-
bodied in the 1,2-dithiole-3-thione nucleus of the molecule.
Recently completedexperiments indicatedthattheunsubstituted
congenerofoltipraz, 1,2-dithiole-3-thione, is also an effective
inhibitor of AFB,-induced tumorigenesis, as determined by
analyses for preneoplastic foci expressing either -y-glutamyl-
transpeptidase (+) or glutathione-S-transferase-7r (15). These
datajustified anexamination oftheimpactofchemoprotection
by 1,2-dithiole-3-thione on the molecular dosimetry of AFB-
N7-guanine in urine and to compare the modulation of this
biomarkerwithlevelsofaflatoxin-DNAadductsintheliver(10).
The effects of 1,2-dithiole-3-thione on the kinetics ofhepatic
aflatoxin-DNAadductformationandremoval in ratsreceiving
250 yg AFB,/kg by gavage on each of days 0-4 and 7-11 are
shown in Figure9. Maximal levels ofcarcinogen binding were
achieved following the third dose in the control group and
declinedthereafterdespitecontinuedexposuretoaflatoxin. This
diminutionofbinding, particularly duringtheseconddosingcy-
cle, hasbeenobserved previously (16-18) and may be a conse-
quenceoftheinductionofglytathioneS-transferasesand/orother
enzymes involved inAFB1 detoxincationfollowingchronic ex-
posure toaflatoxin (15). Inclusionof0.03% 1,2-dithiole-3-thione
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FIGURE 9. Effect of 1,2-dithiole-3-thione on levels ofaflatoxin-DNA adducts
in rat liver. DNA was isolated from the livers ofrats fed either control or
1,2-dithiole-3-thione-supplemented dietsaftermultipleadministrations of
aflatoxinB, (AFB,); 250 Agof[3H]AFB, wereadministeredperosondays
0-4 and 7-11 as indicated by arrows. Rats were placed on 1,2-dithiote-3-
thione-supplemented diet 1 weekbefore initiationofAFB, dosingand main-
tained onthisdietforthedurationoftheexperiment.(O)Control diet; (1B )
0.03% 1,2-dethiole-3-thione-supplemented diet. Values are means ofdeter-
minations doneon two rats/group/day (10).
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inthediet, beginning 1 weekbeforedosingwithAFBI, resulted
in substantially lowerlevelsofhepaticaflatoxin-DNA adducts
throughout the exposureperiod. Binding was reduced by 76%
over the initial 18-day period.
PresentedinFigure 10arethelevelsoftotalaflatoxinequiva-
lents in24-hrurinesamplescollectedoverthe2-weekexposure
period. There are no remarkable differences in the levels of
aflatoxin metabolites in rats fedthecontrol AIN-76Adiet com-
paredtothosefedthe 1,2-dithiole-3-thione-supplemented diet.
Urinaryaflatoxin levelsriserapidlyafterdosingwithAFB1 and
drop equally quickly after cessation ofdosing, reflecting the
overall shortin vivohalf-lifeofthis carcinogen. The lackofan
effect by 1,2-dithiole-3-thione is not surprising given that ex-
posurestoAFB1 wereidenticalinbothdietarygroups. However,
adistinctly differentpattern emergeswhentheurinesweresub-
jected to sequential monoclonal antibody immunoaffinity
chromatographyand HPLC. ShowninFigure 11 arethelevelsof
AFB-N7-guanine in serial 24-hr urine samples collected from
rats undergoing a chemoprotective intervention with 0.03%
1,2-dithiole-3-thione. ThehighestlevelofAFB-N7-guanineex-
cretionoccurred onday 2 inboth groups after thethird doseof
AFB,. This outcome is identical to that observed with hepatic
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FIGURE 10. Elimination oftotal aflatoxin equivalents in urine following multi-
ple exposures toaflatoxinB1. Animals weretreated asdescribedinthelegend
to Figure 9. (O) control diet; (U) 0.03% 1,2dithiole-3-thione-supplemented
diet. Values are meansofserial determinations done on fourrats/group(10).
50
URINE
z
Z 40
O 8 1 2 4 1 0m 121
DAYS
FIGURE 11. Effect of 1,2-dithiole-3-thione on levels of aflatoxin (AFB)-
N7-guanine in urine after multiple exposures to AFB,. Animals were treated
as described in the legendtoFigure9and AFB-N7-guanine levels determined.
(OI) Control diet; (fA)0.03% 1,2-dithiole-3-thione-supplemented diet. Values
are means of serial determinations done on four rats/group (JO), n.d., not
detectable.
levelsofaflatoxin-DNA adducts (Figure9). Overthe 15-daycol-
lection period in which AFB-N7-guanine adducts were detec-
tableintheurine, feedingof 1,2-dithiole-3-thione produced an
overall reduction of62% in the elimination ofthis aflatoxin-
DNAadductexcisionproduct, mirroringthedataontheoverall
levels ofhepatic aflatoxin-DNA adducts depicted in Figure 9.
TheamountofAFB-N7-guanineinurinerepresentsonly 1% of
the total aflatoxin metabolites in urine and accounts for the
dramatic differences seen between treatment groups in AFB-
N7-guanine levels, which are not reflected in the levels oftotal
urinary aflatoxin metabolites shown in Figure 11.
Discussion
Prevention strategies for hepatocellular carcinoma offer the
besthope toeventually lower liver cancer incidence. In recent
years hepatitis B virus (HBV) vaccination programs have been
started toachieve this goal; however, this intervention is effec-
tiveonly whengiventoanuninfectedperson. Becausethisvirus
commonlyinfectspeoplebeforetheyare2yearsold, manyyears
willberequiredbeforevaccinationsofindividuals wouldbeex-
pected to result in lower cancer rates. In addition, the lack of
knowledge regarding the mechanism of HBV induction of
primaryhepatocellularcarcinomaandpossibleinteractionwith
aflatoxinhasmadeitdifficulttoassesstheroleofaflatoxininthe
etiology ofthetumor. Thus, ifexposuretodietaryaflatoxinscan
be lowered, reduction indisease rates may occurearlierand to
agreaterextent. Interestinaflatoxinasariskfactorforhuman
livercancerhasbeenheightenedby recentreportswhichshowed
that one-halfofthe human liver tumors examined from China
andSouthernAfricahadahotspotguaninetothyminetransver-
sionmutationinthetumorsuppressorgene,p53, atcodon249.
Givenpreviousexperimentaldatashowingthataflatoxincauses
thistypeofmutation, thesuggestionwasraisedthatAFB, could
be an etiological agent for these tumors (19,20). Recent work
fromourlaboratory has shownthataflatoxin-epoxide canbind
tothisparticularcodon249ofp53 inaplasmid, providing fur-
therindirectevidenceforaputativeroleofaflatoxinexposurein
p53mutagenesis(21). ThebiologicalimportanceofmutantpS3
isbeingsuggestedforawidenumberofhumantumors(22), and
the molecular dosimetry methods described in this paper for
AFB-N7-guanineinurinemaybecomeusefulinepidemiological
investigations to examinethe role ofthis gene in livercancer.
The damage ofDNA aflatoxin is only oneofmany potential
factors involved in the etiopathogenesis ofliver cancer. Many
otherfactors, including, forexample, recurrentcytotoxicity, cell
proliferation, andnutritionalstatuscouldstronglyinfluencethe
diseaseprocess. Thus, molecularepidemiological investigations
that examine only one biomarker may greatly under- or over-
estimate theriskfor an individual.
In our experimental studies, we have found the need to
measurespecific,biologicallyrelevantmetbolitesinaurinesam-
ple. This is illustrated by the data shown in Figure 10, which
demonstratethatthelevelsofthedailyurinaryexcretionoftotal
aflatoxinmetabolites areunrelatedtoriskofaflatoxin-induced
disease. Similaranalysesusing thehumanurine samples from
Chinaalsorevealedthattotalaflatoxinmetabolitesinurinedonot
reflectappropriateexposureassessments. Intheratmodel itis
aminor, butbiologicallyrelevantmetabolite, AFB-N7-guanine,
repressenting less than 1% of the excreted material in urine,
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which does reflectexposure inexperimental models. Thus, the
composite human and experimental data generated from our
research indicates thatacautious interpretation ofthe relation-
ship between any biomarker and tumor outcome must be
employed. InarecentreportbyCampbelletal. (23), noassocia-
tionbetweencompositeaflatoxinmetabolites inhumanurineand
livercancerdisease rateswasfoundforthePeople's Republicof
China, which is consistent with our finding thatthese two out-
comes are notbiologically related.
A significant finding of all of these studies was the dose-
dependent relationship between aflatoxin exposure and the ex-
cretion ofthe major DNA adduct, AFB-N7-guanine, in urine.
Using the data obtained from China, about 0.2% ofthe AFB1
dose was excreted as AFB-N7-guanine in urine. This value is
similar to excretion ofAFB-N7-guanine in dosed rats, where
0.6% ofAFBI isfoundastheDNAadductinurine. Thus, work
intheratmodelsappearstoyieldsimilarexcretionpatternscom-
pared to humans.
Finally, the rapidly excreted AFB-N7-guanine adduct only
reflects relatively recentexposurestoAFB1. Temporalrelation-
shipsbetween DNAdamageandlong-term riskfromexposure
inhumans remains tobeestablished. Thispotential association
will be examined in future studies, in conjunction with other
biomarkers thatgive an integration ofexposure over a number
ofweeks such as aflatoxin-albumin adducts in serum, and will
eventuallybetesteddirecdythroughprospectiveepidemiological
investigations.
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